Ranibizumab for the Inhibition of Neovascularization in Pterygia
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab
given via subconjunctival injection in patients undergoing pterygium surgery.